Vital Biopharmaceutical Insights and Analytics

Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Featured Service
Major Depressive Disorder

The recent decision by the U.S. Food and Drug Administration (FDA) to grant approval of AstraZeneca’s Seroquel XR for adjunctive treatment of major depressive disorder will not change Decision Resources’ market forecast for the indication...Learn More

Featured Webinar
Looking Beyond Triple Therapy for the Hepatitis C Non-Responders Population: U.S. and European Physician Expectations and Perceptions About Quadruple Therapy

February 18, 2010...Learn More

View Webinar schedule and archive

Search Reports

Filter results:

TOP TEN REPORTS

See which reports have been searched on the most.

In the Spotlight

	Donny Wong, Ph.D. February 11, 2010 10 a.m. ET, 4 p.m. CET
In this presentation, Dr. Wong will discuss how sibutramine’s suspension in Europe will impact the obesity drug market... Learn more

Latest Press Releases [ view all ]

February 8, 2010

Emerging Combination Agent from Merck Will Garner Peak Year Sales of More Than $250 Million for the Treatment of Asthma ...Read More
February 4, 2010

By 2018, AVEO Pharmaceuticals’ Tivozanib Will Garner Sales of up to $100 Million in the Renal Cell Carcinoma Drug Market ...Read More
February 2, 2010

Spiriva Will Remain Decision Resources’ Clinical Gold Standard Through 2018 for the Treatment of Chronic Obstructive Pulmonary Disease ...Read More

Recent Reports [ view all ]

Strategic Overview of the Targeted Cancer Therapies Marketplace

The allure of blockbuster revenues, like those earned by Roche/Chugai’s targeted cancer drugs Avastin, Herceptin,... Read More
Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms (Event Driven)

Last Updated 5 February 2010
Lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia... Read More
Antivirals: Novel Targets, Technologies, and Dealmaking

The hottest field in antivirals is hepatitis C virus (HCV) drug development; compounds against novel HCV targets such... Read More